EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study

Xudong Xie, Siyuan Chen iD, Yawei Cui, Zhenzhen Zhou, Jianhua Lu, Zhi Du iD, Jie Ding, Kaidi Xing, Yuesheng Zhang, Yijiang Zhou iD, Jun Li, Xiaogang Guo iD

Journal of the American Heart Association · 06.08.2024 · 13 (15)

DOI: 10.1161/jaha.123.034080 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 06.08.2024. Verfasst von Xudong Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, School of Medicine Zhejiang University Zhejiang China. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Septum. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported to be safe and effective at midterm follow‐up to treat drug‐refractory hypertrophic obstructive cardiomyopathy in a single center. However, data from other centers are lacking. This retrospective cohort study aimed to investigate the efficacy and safety of PIMSRA from another independent center. Methods and Results PIMSRA was performed in 76 patients with hypertrophic obstructive cardiomyopathy in our center from April 2020 to June 2023. The primary outcome was the reduction of left ventricular outflow tract gradient after 6 months or more post‐PIMSRA. Secondary outcomes were periprocedural major adverse clinical events. Sixty‐one patients returned to the hospital for follow‐up 6 to 30 (median, 14) months after the procedure. At the last follow‐up of the 61 patients, the maximum septal thickness decreased from a median of 23.6 (interquartile range, 20.5–26.4) to 19.1 (interquartile range, 16.0–22.1) mm ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHeart SeptumHumansMaleFemaleMiddle AgedRetrospective StudiesTreatment OutcomeAgedCatheter AblationTime FactorsRadiofrequency AblationAdultVentricular Function, LeftFollow-Up StudiesEchocardiography

Stichwörter der Autor:innen

echocardiographyhypertrophic obstructive cardiomyopathymidterm follow‐uppercutaneous intramyocardial septal radiofrequency ablation

Autor:innen und Institutionen

  • Department of Cardiology, The First Affiliated Hospital, School of Medicine Zhejiang University Zhejiang China.
  • Graduate School Zhejiang University School of Medicine Hangzhou China.

ORCID-Profile: Siyuan Chen, Zhi Du, Yijiang Zhou, Xiaogang Guo

Zitieren

APA

Xie, X., Chen, S., Cui, Y., Zhou, Z., Lu, J., Du, Z., Ding, J., Xing, K., Zhang, Y., Zhou, Y., Li, J., & Guo, X. (2024). Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study. Journal of the American Heart Association, 13(15). https://doi.org/10.1161/jaha.123.034080

Vancouver

Xie X, Chen S, Cui Y, Zhou Z, Lu J, Du Z, et al. Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study. Journal of the American Heart Association. 2024;13(15). doi:10.1161/jaha.123.034080

BibTeX
@article{Xie2024,
  author = {Xie, Xudong and Chen, Siyuan and Cui, Yawei and Zhou, Zhenzhen and Lu, Jianhua and Du, Zhi and Ding, Jie and Xing, Kaidi and Zhang, Yuesheng and Zhou, Yijiang and Li, Jun and Guo, Xiaogang},
  title = {Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single‐Center, Observational Study},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {15},
  doi = {10.1161/jaha.123.034080}
}
Kostenlos starten →